<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Summary of immunomodulatory agents for the management of COVID-19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Treatments</th>
    <th align="left">Dosing regimens under investigation</th>
    <th align="left">Route of administration under investigation</th>
    <th align="left">Mode of action</th>
    <th align="left">Common adverse events</th>
    <th align="left">Contraindications (US labeling)</th>
    <th align="left">Major drug interactions</th>
    <th align="left">Use in specific populations</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" colspan="8">
     <italic>Specific immunomodulators</italic>
    </td>
   </tr>
   <tr>
    <td align="left">Anakinra</td>
    <td align="left">
     <p>IV: 100 mg every 6 h (total daily dose: 400 mg) for 15 days; 200 mg every 8 h for 7 days; 300 mg od for 4 days, followed by 100 mg od</p>
     <p>SC: 100 mg od for 10 or 28 days. Alternative regimen: 100 mg every 12 h on days 1–3, then 100 mg od from days 4–10</p>
    </td>
    <td align="left">
     <p>IV, SC</p>
     <p>Note: IV route is currently not FDA-approved</p>
    </td>
    <td align="left">Anti-cytokine, IL-1 receptor antagonist</td>
    <td align="left">Injection site reactions, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, flu-like symptoms, abdominal pain</td>
    <td align="left">Known hypersensitivity to 
     <italic>Escherichia coli</italic>-derived proteins, anakinra, or any component of the product
    </td>
    <td align="left">Avoid use with anti-TNF agents due to higher rates of infections and neutropenia</td>
    <td align="left">
     <p>Use caution in the elderly due to higher rates of infections in the elderly population</p>
     <p>In patients with CrCl &lt; 30 and ESRD, use extended dosing intervals (every other day)</p>
    </td>
   </tr>
   <tr>
    <td align="left">Tocilizumab</td>
    <td align="left">4–8 mg/kg (maximum single dose: 800 mg), may repeat after 12 h</td>
    <td align="left">
     <p>IV</p>
     <p>No trials evaluating the SC form</p>
    </td>
    <td align="left">Anti-cytokine, IL-6 receptor antagonist</td>
    <td align="left">Injection site reactions, upper respiratory tract infections (including tuberculosis), nasopharyngitis, headache, hypertension, increased ALT, hematological effects</td>
    <td align="left">Known hypersensitivity to tocilizumab</td>
    <td align="left">May decrease serum concentration of CYP3A4 substrates</td>
    <td align="left">Safety during pregnancy and lactation is unknown</td>
   </tr>
   <tr>
    <td align="left">Sarilumab</td>
    <td align="left">Not described</td>
    <td align="left">
     <p>IV</p>
     <p>Note: IV route is currently not FDA-approved</p>
    </td>
    <td align="left">Anti-cytokine, IL-6 receptor antagonist</td>
    <td align="left">Neutropenia, increased ALT, injection site erythema, upper respiratory infections, urinary tract infections</td>
    <td align="left">Known hypersensitivity to sarilumab or any of its inactive ingredients</td>
    <td align="left">May decrease serum concentration of CYP3A4 substrates</td>
    <td align="left">Safety during pregnancy and lactation is unknown</td>
   </tr>
   <tr>
    <td align="left">Ruxolitinib</td>
    <td align="left">
     <p>Various regimens under investigation</p>
     <p>5 mg bid for 14 days; 10 mg bid; 2 × 10 mg bid dose at day 1 and can be increased up to 2 × 15 mg bid from day 2 to day 28; 5 mg bid from day 1 to day 3 then 10 mg bid from day 4 to day 10; 10 mg bid, for 14 days followed by 5 mg bid for 2 days and 5 mg od for 1 day</p>
    </td>
    <td align="left">PO</td>
    <td align="left">Anti-cytokine, JAK1/JAK2 inhibitor</td>
    <td align="left">Thrombocytopenia, neutropenia, anemia, infections, edema, headache, dizziness</td>
    <td align="left">None</td>
    <td align="left">CYP3A4 substrate. Serum roxulitinib levels may increase when used with CYP3A4 inhibitors (i.e. ritonavir)</td>
    <td align="left">
     <p>Use in pregnant and lactating women is not recommended</p>
     <p>May require starting dose reduction in hepatic and renal impairment</p>
    </td>
   </tr>
   <tr>
    <td align="left">Baricitinib</td>
    <td align="left">2 or 4 mg od for 14 days</td>
    <td align="left">PO</td>
    <td align="left">Anti-cytokine, JAK1/JAK2 inhibitor</td>
    <td align="left">Upper respiratory tract infections, nausea, herpes simplex, herpes zoster</td>
    <td align="left">None</td>
    <td align="left">
     <p>Substrate of BCRP/ABCG2, CYP3A4, OAT1/3, P-gp/ABCB1</p>
     <p>Avoid use with strong OAT3 inhibitors</p>
    </td>
    <td align="left">Avoid use in patients with severe hepatic impairment, and in patients with moderate or severe renal impairment</td>
   </tr>
   <tr>
    <td align="left">Adalimumab</td>
    <td align="left">Not described</td>
    <td align="left">Injection, specifics not described</td>
    <td align="left">Anti-cytokine, anti-TNFα</td>
    <td align="left">Upper respiratory tract infections, sinusitis, increased macrophage-dependent infection, tuberculosis, opportunistic infections, injection site reactions, increased creatine phosphokinase, headache, rash</td>
    <td align="left">None</td>
    <td align="left">Avoid use with anakinra due to higher rates of infections and neutropenia</td>
    <td align="left">
     <p>Use with caution in patients with heart failure or decreased left ventricular function; may cause myocardial toxicity or exacerbate underlying myocardial dysfunction</p>
     <p>Use caution in elderly patients; may increase infection risk</p>
    </td>
   </tr>
   <tr>
    <td align="left">Sargramostim</td>
    <td align="left">125 μg bid for 5 days</td>
    <td align="left">Nebulized inhalation</td>
    <td align="left">Recombinant humanized GM-CSF</td>
    <td align="left">Fever, hypertension, edema, pericardial effusion, chest pain, peripheral edema, tachycardia, central nervous system effects, dermatologic effects, endocrine and metabolic changes, GI effects, urinary tract infections, hyperbilirubinemia, neuromuscular and skeletal effects, retinal hemorrhage, increased serum creatinine, pharyngitis, epistaxis, dyspnea
     <sup>a</sup>
    </td>
    <td align="left">Hypersensitivity to human GM-CSF, yeast-derived products, or any component of the formulation</td>
    <td align="left">May enhance myeloproliferative effects when administered with products that induce myeloproliferation (e.g. corticosteroids)</td>
    <td align="left">
     <p>Use with caution in patients with pre-existing cardiac disease; may cause supraventricular arrhythmia</p>
     <p>Safety during pregnancy and lactation is unknown</p>
    </td>
   </tr>
   <tr>
    <td align="left">Gimsilumab (investigational molecule)</td>
    <td align="left">High dose on day 1 and low dose on day 8, specifics not described</td>
    <td align="left">IV</td>
    <td align="left">Anti-GM-CSF</td>
    <td align="left">Not described</td>
    <td align="left">Not described</td>
    <td align="left">Not described</td>
    <td align="left">Not described</td>
   </tr>
   <tr>
    <td align="left">Convalescent plasma</td>
    <td align="left">One or two infusions. Titer depends on donor</td>
    <td align="left">IV</td>
    <td align="left">Neutralizing antibodies provide short-term passive immunity</td>
    <td align="left">Inadvertent transmission of infectious agents, allergic reactions, thrombotic complications, transfusion-associated circulatory overload, transfusion-related acute lung injury</td>
    <td align="left">
     <p>Allergy to human plasma, sodium citrate, methylene blue</p>
     <p>IgA-deficient patients with antibodies to IgA and a history of hypersensitivity</p>
    </td>
    <td align="left">None</td>
    <td align="left">Not recommended in patients with heart failure, chronic kidney failure in the dialysis phase, and organ transplant</td>
   </tr>
   <tr>
    <td align="left" colspan="8">
     <italic>Non-specific immunomodulators</italic>
    </td>
   </tr>
   <tr>
    <td align="left">IVIG</td>
    <td align="left">0.3–0.5 g/kg daily for 5 days</td>
    <td align="left">IV</td>
    <td align="left">Antibodies from pooled plasma provide short-term passive immunity</td>
    <td align="left">Headache, nausea, fever, chills, dyspnea, cough, sore throat, malaise, myalgia, arthralgia, abdominal pain, leukopenia, aseptic meningitis, infections, acute renal failure, stroke, myocardial infarction, deep vein thrombosis, pulmonary embolism, anaphylactic shock</td>
    <td align="left">
     <p>History of anaphylactic or severe systemic reaction to human immune globulin</p>
     <p>Patients with hyperprolinemia; IVIG contains stabilizer L-proline</p>
     <p>IgA-deficient patients with antibodies to IgA and a history of hypersensitivity</p>
    </td>
    <td align="left">Live virus vaccines (measles, mumps, rubella, varicella)</td>
    <td align="left">Use with caution in elderly patients; may be at higher risk for renal failure and thromboembolic events. Administer the minimum dose at the lowest infusion rate practical</td>
   </tr>
   <tr>
    <td align="left">Dexamethasone</td>
    <td align="left">RECOVERY trial: 6 mg daily for 10 days; DEXA-COVID19 trial: 20 mg od from day 1 to day 5, followed by 10 mg od from day 6 to day 10</td>
    <td align="left">IV or PO</td>
    <td align="left">Provide anti-inflammatory and antifibrotic effects to prevent extended cytokine response</td>
    <td align="left">Sodium and water retention (less than methylprednisolone), hypertension, hyperglycemia, osteoporosis, cardiac hypertrophy, edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravis</td>
    <td align="left">Hypersensitivity to corticosteroids or any component of the formulation, systemic fungal infection</td>
    <td align="left">Substrate of CYP3A4 and P-gp/ABCB1. Live or attenuated virus vaccines (if using immunosuppressive doses of corticosteroids)</td>
    <td align="left">Use with caution in the elderly with the smallest possible effective dose for the shortest duration</td>
   </tr>
   <tr>
    <td align="left">Methylprednisolone</td>
    <td align="left">
     <p>0.5–1 mg/kg daily or 1–2 mg/kg daily (of methylprednisolone or equivalent) have been proposed</p>
     <p>Higher doses (cytokine storm): 60–125 mg (methylprednisolone) every 6 h for up to 3 days</p>
    </td>
    <td align="left">IV</td>
    <td align="left">Provide anti-inflammatory and antifibrotic effects to prevent extended cytokine response</td>
    <td align="left">Sodium and water retention, hypertension, hyperglycemia, osteoporosis, cardiac hypertrophy, edema, hypokalemia, bruising, diaphoresis, urticaria, allergic rash, euphoria, psychosis, infections, myasthenia gravis</td>
    <td align="left">Hypersensitivity to corticosteroids or any component of the formulation, systemic fungal infection</td>
    <td align="left">
     <p>CYP3A4 substrate</p>
     <p>Live or attenuated virus vaccines (if using immunosuppressive doses of corticosteroids)</p>
    </td>
    <td align="left">
     <p>Use with caution in the elderly, with the smallest possible effective dose for the shortest duration</p>
     <p>Note: Oral corticosteroids should be continued in COVID-19 patients with an underlying condition (e.g. primary or secondary adrenal insufficiency, rheumatologic diseases)</p>
     <p>Inhaled corticosteroids should be continued in COVID-19 patients with asthma and COPD</p>
     <p>Corticosteroid treatment in pregnant women should be individualized; benefits should be weighed with potential harm</p>
    </td>
   </tr>
   <tr>
    <td align="left">Interferon-β-1b</td>
    <td align="left">0.25 mg (8 million units) for 3 days; days 1, 2, 3, or days 1, 3, 5</td>
    <td align="left">SC</td>
    <td align="left">Antiviral and immunomodulator</td>
    <td align="left">Peripheral edema, skin rash, abdominal pain, urinary urgency, leukopenia, lymphocytopenia, neutropenia, increased ALT, injection site reaction, ataxia, chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever</td>
    <td align="left">History of hypersensitivity to natural or recombinant interferonβ, albumin (human), or any component of the formulation</td>
    <td align="left">No formal drug interaction studies have been conducted</td>
    <td align="left">Use with caution in patients with bone marrow suppression, cardiovascular disease, hepatic impairment</td>
   </tr>
   <tr>
    <td align="left">Interferon-α-2b</td>
    <td align="left">5 million units bid</td>
    <td align="left">Nebulized</td>
    <td align="left">Antiviral and immunomodulator</td>
    <td align="left">Skin rash, abdominal pain, leukopenia, lymphocytopenia, neutropenia, increased ALT, injection site reaction, ataxia, chills, headache, hypertonia, insomnia, asthenia, myalgia, flu-like symptoms, fever, hemolytic anemia</td>
    <td align="left">Hypersensitivity to interferon-α or any component of the formulation, decompensated liver disease, autoimmune hepatitis</td>
    <td align="left">Not fully evaluated</td>
    <td align="left">Use with caution in patients with a history of neuropsychiatric, autoimmune, ischemic, infectious disorders, and patients with pre-existing heart disease and organ transplant</td>
   </tr>
   <tr>
    <td align="left" colspan="8">
     <italic>Miscellaneous</italic>
    </td>
   </tr>
   <tr>
    <td align="left">Statins</td>
    <td align="left">Simvastatin 40 mg od for 14 days, simvastatin 80 mg od, atorvastatin 40 mg od</td>
    <td align="left">PO</td>
    <td align="left">Anti-inflammatory and immunomodulatory effects</td>
    <td align="left">Hepatotoxicity, myopathies, GI effects, rhabdomyolysis, increased risk of diabetes</td>
    <td align="left">Hypersensitivity to statin or any component of the formulation, active liver disease; unexplained persistent elevations of serum transaminases; pregnancy, breastfeeding</td>
    <td align="left">Inhibitors/substrates of CYP3A4 may increase statin concentrations</td>
    <td align="left">
     <p>Use with caution in elderly patients; may be at higher risk for myopathy</p>
     <p>Statins may need to be withheld for a short time period in COVID-19 patients with severe rhabdomyolysis</p>
    </td>
   </tr>
   <tr>
    <td align="left">ACEi/ARB</td>
    <td align="left">Various dosing regimens: telmisartan 80 mg bid, telmisartan 40 mg bid, ramipril 2.5 mg od for 14 days, losartan 100 mg od, valsartan 80 or 160 mg for 14 days (max: 160 mg bid), captopril 25 mg, losartan 25 mg od, losartan 50 mg od</td>
    <td align="left">PO</td>
    <td align="left">Anti-inflammatory and immunomodulatory effects</td>
    <td align="left">Cough (more common with ACEi), hyperkalemia, edema, angioedema (more common with ACEi), photosensitivity, renal failure, dysgeusia, headache</td>
    <td align="left">Previous angioneurotic edema (ACEi), pregnancy, hyperkalemia, bilateral renal stenosis, pregnancy</td>
    <td align="left">Risk of hyperkalemia may be increased when combined with potassium-increasing medications</td>
    <td align="left">Treatment should be continued in COVID-19 patients with an indication for ACEi/ARB; abrupt withdrawal may lead to clinical instability</td>
   </tr>
   <tr>
    <td align="left">Azithromycin</td>
    <td align="left">500 mg on day 1, then 250 mg od on days 2–5 in conjunction with a 10-day regimen of hydroxychloroquine</td>
    <td align="left">PO</td>
    <td align="left">Anti-inflammatory and immunomodulatory effects</td>
    <td align="left">QTc prolongation and ventricular arrhythmias, diarrhea, nausea, abdominal pain, vomiting</td>
    <td align="left">Hypersensitivity to azithromycin or other macrolides, history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use</td>
    <td align="left">Inhibits P-gp/ABCB1</td>
    <td align="left">Elderly patients may be more susceptible to development of Torsades de pointes arrhythmias</td>
   </tr>
   <tr>
    <td align="left">Hydroxychloroquine</td>
    <td align="left">400 mg bid on day 1, then 200 mg bid on days 2–5; 400 mg od for 5 days; 200 mg tid for 10 days; 100–200 mg bid for 5–14 days</td>
    <td align="left">PO</td>
    <td align="left">Anti-inflammatory and immunomodulatory effects</td>
    <td align="left">QTc prolongation, abdominal pain, decreased appetite, diarrhea, nausea, vomiting, hemolysis in G-6-PD deficiency, hypoglycemia, retinopathy, nervous system disorders, psychiatric disorders</td>
    <td align="left">Known hypersensitivity to hydroxychloroquine, 4-aminoquinoline derivatives, or any component of the formulation</td>
    <td align="left">
     <p>CYP2D6, CYP2C8, CYP3A4, CYP3A5</p>
     <p>Coadministration of chloroquine phosphate or hydroxychloroquine sulfate and remdesivir may result in reduced antiviral activity of remdesivir</p>
    </td>
    <td align="left">Caution should be exercised when administering to pregnant and nursing mothers</td>
   </tr>
   <tr>
    <td align="left">Colchicine</td>
    <td align="left">0.5 mg bid for 3 days, then 0.5 mg od for 27 days</td>
    <td align="left">PO</td>
    <td align="left">Anti-inflammatory and immunomodulatory effects</td>
    <td align="left">GI symptoms (diarrhea, nausea, vomiting, abdominal pain), neuromuscular toxicity, hematological effects, elevated AST and ALT</td>
    <td align="left">Renal or hepatic impairment in conjunction with drugs that inhibit both CYP3A4 and P-gp (e.g. clarithromycin)</td>
    <td align="left">
     <p>Substrate of CYP3A4, P-gp/ABCB1</p>
     <p>Dose adjustment of colchicine is required in patients taking protease inhibitors (e.g. lopinavir/ritonavir)</p>
    </td>
    <td align="left">Dose adjustment is required in patients with renal or hepatic function</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>ACEi</italic> angiotensin-converting enzyme inhibitors, 
   <italic>ALT</italic> alanine aminotransferase, 
   <italic>ARB</italic> angiotensin II receptor blockers, 
   <italic>AST</italic> aminotransferase, 
   <italic>bid</italic> twice daily, 
   <italic>COPD</italic> chronic obstructive pulmonary disease, 
   <italic>COVID-19</italic> coronavirus disease 2019, 
   <italic>CrCl</italic> creatinine clearance, 
   <italic>CYP</italic> cytochrome P450, 
   <italic>ESRD</italic> end-stage renal disease, 
   <italic>G-6-PD</italic> glucose-6-phosphate dehydrogenase, 
   <italic>GI</italic> gastrointestinal, 
   <italic>GM-CSF</italic> granulocyte–macrophage colony-stimulating factor, 
   <italic>IgA</italic> immunoglobulin A, 
   <italic>IL</italic> interleukin, 
   <italic>IV</italic> intravenous, 
   <italic>IVIG</italic> intravenous immunoglobulin, 
   <italic>JAK</italic> Janus kinase, 
   <italic>max</italic> maximum, 
   <italic>OAT</italic> organic anion transporter, 
   <italic>od</italic> once daily, 
   <italic>P-gp</italic> P-glycoprotein, 
   <italic>PO</italic> oral, 
   <italic>SC</italic> subcutaneous, 
   <italic>tid</italic> three times daily, 
   <italic>TNF</italic> tumor necrosis factor
  </p>
  <p>
   <sup>a</sup>Reported with the IV and SC forms of the drug
  </p>
 </table-wrap-foot>
</table-wrap>
